Search Results - Benjamin Nicholson
- Showing 1 - 6 results of 6
-
1
-
2
-
3
1056 XTX301, a tumor activated, half-life extended IL-12 promoted potent anti-tumor immunity and activity across multiple syngeneic tumor models by Wilson Guzman, Damiano Fantini, Parker Johnson, Kurt Jenkins, Hanumantha Rao Madala, Caitlin O’Toole, Magali Pederzoli-Ribeil, Jennifer O’Neil, Jake Taylor, Ekta Patel, Sallyann Vu, Manoussa Fanny, Oleg Yerov, Benjamin Nicholson, Natalia V Malkova, Stephanie Hsiao, Ertan Eryilmaz, Uli Bialucha
Published in Journal for ImmunoTherapy of Cancer (2023-11-01)Article -
4
719 XTX301, a protein-engineered IL-12, exhibits tumor-selective activity in mice without peripheral toxicities and is well tolerated in non-human primates by Jia Chen, Wilson Guzman, Parker Johnson, Megan McLaughlin, Kurt Jenkins, Hanumantha Rao Madala, Magali Pederzoli-Ribeil, Huawei Qiu, Ekta Patel, Natalia Malkova, Sallyann Vu, Rebekah O'Donnell, Manoussa Fanny, Oleg Yerov, Caitlin O'Toole, Benjamin Nicholson, Bill Avery, Ronan O'Hagan, Jennifer O'Neil
Published in Journal for ImmunoTherapy of Cancer (2021-11-01)Article -
5
Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3+ T-regulatory Cell Function and Promotes Antitumor Immunity by Liqing Wang, Suresh Kumar, Satinder Dahiya, Feng Wang, Jian Wu, Kheng Newick, Rongxiang Han, Arabinda Samanta, Ulf H. Beier, Tatiana Akimova, Tricia R. Bhatti, Benjamin Nicholson, Mathew P. Kodrasov, Saket Agarwal, David E. Sterner, Wei Gu, Joseph Weinstock, Tauseef R. Butt, Steven M. Albelda, Wayne W. Hancock
Published in EBioMedicine (2016-11-01)Get full text
Article -
6
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer by Zhen Liu, Wilson Guzman, Parker Johnson, Megan McLaughlin, Caitlin O’Toole, Magali Pederzoli-Ribeil, Huawei Qiu, Margaret Karow, Tim Clackson, Jennifer O’Neil, Ugur Eskiocak, Miso Park, Benjamin Nicholson, John C Williams, Kurt A Jenkins, Deborah Moore-Lai, Veronica Flesch, Ronan C O’Hagan, Ulrich Rodeck
Published in Journal for ImmunoTherapy of Cancer (2023-12-01)Get full text
Article
